Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
NCT01467882
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Precocious Puberty
Interventions
DRUG:
Triptorelin
Sponsor
Debiopharm International SA